Resources

Drug Topics Features InCrowd Biosimilars Market Research
By Charu Gupta

Most U.S. physicians plan to prescribe biosimilars in the next three years, but they won’t be making the decision to do so lightly, according to tracking market research survey data from InCrowd. Physicians have also upped the number of factors they’ll weigh before switching patients to FDA approved biologic drugs that are similar yet not identical to the ones already being prescribed. A recent article in Drug Topics, Issues About Biosimilar Substitution,” features our in-depth research.

Some of the comments InCrowd received from physicians included, “At this time I would not be amenable to switching a patient from a stable medication without significant data to prove complete compatibility” from a rheumatologist and “I would wait and let other doctors experiment on their patients,” from an oncologist.

InCrowd President and Co-Founder Diane Hayes is surprised that more physicians are not familiar with – and willing to prescribe – biosimilars. “With four biosimilars available now, not just one, I’m surprised that that substantially more docs aren’t…more familiar with biosimilars.

Read Full Article

Related Resources

Employee Spotlight: Mili Bhatia

Employee Spotlight: Mili Bhatia

Mili is the SVP of Client Services at Survey Healthcare Global, the client research side of OpinionSite. Get to know more about her below! What do you love about working in the life science industry? I love that part of what we do impacts healthcare, with the ultimate...

read more
Pride and Visibility: Perspective from a New Grad RN

Pride and Visibility: Perspective from a New Grad RN

This is the first Pride Month that I am ringing in as a registered nurse, and while I have been out and proud for 13 years or so, I’m experiencing a renewed connection to the importance of celebrating my community. As the corporate rainbows unfurled, we heard the...

read more